Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Completes R&D Leadership Transition To Kim; Spotlight On Genomics

Executive Summary

Merck's effort in genomics will take on a new focus under new R&D head Peter Kim, PhD

You may also be interested in...



Merck Won’t Go Hollywood: In-House R&D Still Focus As Outside Deals Expand

Merck is on a pace to sign 50 outside R&D alliances during 2003

Merck Won’t Go Hollywood: In-House R&D Still Focus As Outside Deals Expand

Merck is on a pace to sign 50 outside R&D alliances during 2003

Singulair Allergy Approval Will Drive Sales Despite OTC Claritin, Merck Says

Merck's Singulair allergic rhinitis indication will help accelerate growth for the asthma drug in 2003, despite the onset of OTC Claritin, Investor Relations Senior Director Mark Stejbach told investors on a Dec. 5 conference call

Related Content

UsernamePublicRestriction

Register

PS040912

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel